The deal with Bayer AG is CuraGen Corp.'s second alliance geared to helping it move downstream into product development.

CRGN's business model hinges on developing into a company that "translates the genome into a product," Chairman and CEO Jonathan Rothberg told BioCentury. Though it expects to enter additional partnerships to bring in chemistry expertise and develop small molecule leads, CRGN is developing protein targets independently and